Exenatide, a 39-amino acid peptide used for treatment of type 2 diabetes, is known to inhibit gastric emptying and as a result to alter the absorption of orally administered concomitant medications.
Simulations Plus Signs Another Collaboration Agreement
Companies to Cooperate on Development of Advanced Ocular Delivery Simulation
Pharmacokinetic/pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel
To evaluate the maximum tolerated dose (MTD), dose-limiting toxicities (DLT), and pharmacokinetics of liposome-entrapped paclitaxel...
Structural Requirements for Drug Inhibition of the Liver Specific Human Organic Cation Transport Protein 1
The liver-specific organic cation transport protein (OCT1; SLC22A1) transports several cationic drugs including the antidiabetic drug metformin and the anticancer agents oxaliplatin and imatinib.
U.S. FDA Licenses ADMET Predictor™ from Simulations Plus
Adds Property Prediction Software to Earlier GastroPlus(™) Licenses
U.S. National Institutes of Health Renews ClassPharmer Software Licenses
Chemical Genomics Center Renews Five Licenses
Physicochemical characterization of five glyburide powders: a BCS based approach to predict oral absorption.
The purpose of this study was to investigate the suitability of physicochemical parameters of Active Pharmaceutical Ingredients (APIs) as input functions for the Advanced Compartmental Absorption and Transit Model...
Simulations Plus and Roche Sign Multi-year Collaboration
Collaboration to Develop Drug-Drug Interaction Capability in GastroPlus™
Simulations Plus Subsidiary, Words+, Inc., Releases Major New Product
"Conversa(™)" System Offers 12-inch Touch Tablet With Superior Voice Quality And Volume
A cellular conformation-based screen for androgen receptor inhibitors
The androgen receptor (AR), a member of the steroid nuclear receptor family of transcription factors, regulates a wide range of physiological...
Simulations Plus Reports Third Quarter and Nine Months FY2008 Financial Results
Record revenues achieved in both business units
Mechanistic Modeling of Metoprolol Absorption and Pharmacokinetics from Immediate and Modified Release Formulations
As one of the most widely used b-blocking agents, metoprolol is also a popular drug in research studies. A number of published studies describe the pharmacokinetics as well as the pharmacodynamics of…
Simulations Plus Sets Date for Third Quarter Earnings Release and Conference Call
Conference Call to be on Tuesday, July 15, at 4:15 PM EDT
Simulations Plus Releases Major Software Update for its Top Rated Predictive Software
ADMET Predictor™ 3.0 Employs New Technology for Molecular Descriptors, All New Predictive Models
Physicochemical properties of the nucleoside prodrug R1626 leading to high oral bioavailability
The nucleoside analog R1479 is a potent and highly selective inhibitor of NS5b-directed hepatitis C virus (HCV) RNA polymerase in vitro.
Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data
Analogous to the fraction unbound in microsomes (fumic), fraction unbound in hepatocyte incubations (fuhep) is an important parameter in the prediction of intrinsic clearance and potential drug-drug interactions.
PBPK Modeling of Metoprolol and Its Metabolites
Develop a model describing absorption and pharmacokinetics of metoprolol and the formation and pharmacokinetics of its metabolites.
Dynamic Dissolution Testing To Establish In Vitro/In Vivo Correlations for Montelukast Sodium, a Poorly Soluble Drug
The objectives of the study was to develop a dissolution test method that can be used to predict the oral absorption of montelukast sodium, and to establish an in vitro/in vivo correlation (IVIVC) using computer simulations.
U.S. EPA Licenses Simulations Plus’ ADMET Predictor™ Software
Agency Licenses Both Toxicity and New Enslein Metabolism Modules